Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
peroxiredoxin 1 small interfering RNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Inhalation, Local
01
Overview
Peroxiredoxin 1 (PRDX1) small interfering RNA is a targeted RNA interference (RNAi) agent designed to silence the expression of the PRDX1 gene. PRDX1 is an antioxidant enzyme that plays a critical role in redox homeostasis and has been implicated in the progression of various cancers, including clear cell renal cell carcinoma (ccRCC). Research indicates that PRDX1 promotes tumor progression by modulating the EGFR-dependent AKT signaling pathway. By utilizing siRNA to degrade PRDX1 mRNA, the expression of the protein is significantly reduced, which in turn inhibits oncogenic signaling, reduces cell proliferation, and may limit metastasis. While currently utilized primarily as a research tool to validate PRDX1 as a therapeutic target, this modality represents a potential strategy for precision oncology.
- Other names
- PRDX1 siRNAPRDX-1 siRNAPRDX 1 siRNAsiRNA-PRDX1siRNA-PRDX-1siRNA-PRDX 1peroxiredoxin 1 siRNAperoxiredoxin1 siRNAperoxiredoxin-1 siRNAperoxiredoxin 1 small interfering RNAperoxiredoxin1 small interfering RNAperoxiredoxin-1 small interfering RNA
02
Targets
PRDX1 (Peroxiredoxin-1)
Beyond the preview
Go deeper on peroxiredoxin 1 small interfering RNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on peroxiredoxin 1 small interfering RNA.